Supply of products by Generic Health Pty Ltd

Administered by Department of Health, Disability and Ageing

Legislation au C2012G00348 In force Gazette

Legislation content

 

 

THERAPEUTIC GOODS ACT 1989

 

SECTION 14 AND 14A NOTICE

 

 

 

On October 24 2012, the delegate of the Secretary of the Department of Health and Ageing for the purposes of subsection 14 and 14A of the Therapeutic Goods Act 1989 (“the Act”) gave his consent to:

 

(a)   the supply of the following products by Generic Health Pty Ltd, Camberwell, VIC (“the Company”):

  • olanzapine (as benzoate) (OLANZAPINE GENERICHEALTH) 2.5 mg tablet blister pack [Aust R 152124]
  • olanzapine (as benzoate) (OLANZAPINE GENERICHEALTH) 5 mg tablet blister pack [Aust R 152167]
  • olanzapine (as benzoate) (OLANZAPINE GENERICHEALTH) 7.5 mg tablet blister pack [Aust R 152168]
  • olanzapine (as benzoate) (OLANZAPINE GENERICHEALTH) 10 mg tablet blister pack [Aust R 152169]
  • olanzapine (as benzoate) (STADA OLANZAPINE) 2.5 mg tablet blister pack [Aust R 152170]
  • olanzapine (as benzoate) (STADA OLANZAPINE) 5 mg tablet blister pack [Aust R 152171]
  • olanzapine (as benzoate) (STADA OLANZAPINE) 7.5 mg tablet blister pack [Aust R 152172]
  • olanzapine (as benzoate) (STADA OLANZAPINE) 10 mg tablet blister pack [Aust R 152123]
  • olanzapine (as benzoate) (OLANZATABS) 2.5 mg tablet blister pack [Aust R 152174]
  • olanzapine (as benzoate) (OLANZATABS) 5 mg tablet blister pack [Aust R 152175]
  • olanzapine (as benzoate) (OLANZATABS) 7.5 mg tablet blister pack [Aust R 152176]
  • olanzapine (as benzoate) (OLANZATABS) 10 mg tablet blister pack [Aust R 152177]

 

That do not conform with the United States Pharmacopoeia 35 monograph for Olanzapine Tablets in that the products listed above do not comply with the acceptance criterion for Olanzapine related compound B in the Organic Impurities test.

 

Pursuant to subsection 15(1) of the Act, the consent given by the delegate of the Secretary as described above is subject to the following conditions:

 

  1. The acceptance criteria to be applied to “Olanzapine related compound B” in the product specifications is not more than 0.15% at release and not more than 0.5% at expiry for the following products:
    • olanzapine (as benzoate) (OLANZAPINE GENERICHEALTH) 2.5 mg tablet blister pack [Aust R 152124]
    • olanzapine (as benzoate) (OLANZAPINE GENERICHEALTH) 5 mg tablet blister pack [Aust R 152167]
    • olanzapine (as benzoate) (OLANZAPINE GENERICHEALTH) 7.5 mg tablet blister pack [Aust R 152168]
    • olanzapine (as benzoate) (OLANZAPINE GENERICHEALTH) 10 mg tablet blister pack [Aust R 152169]
    • olanzapine (as benzoate) (STADA OLANZAPINE) 2.5 mg tablet blister pack [Aust R 152170]
    • olanzapine (as benzoate) (STADA OLANZAPINE) 5 mg tablet blister pack [Aust R 152171]
    • olanzapine (as benzoate) (STADA OLANZAPINE) 7.5 mg tablet blister pack [Aust R 152172]
    • olanzapine (as benzoate) (STADA OLANZAPINE) 10 mg tablet blister pack [Aust R 152123]
    • olanzapine (as benzoate) (OLANZATABS) 2.5 mg tablet blister pack [Aust R 152174]
    • olanzapine (as benzoate) (OLANZATABS) 5 mg tablet blister pack [Aust R 152175]
    • olanzapine (as benzoate) (OLANZATABS) 7.5 mg tablet blister pack [Aust R 152176]
    • olanzapine (as benzoate) (OLANZATABS) 10 mg tablet blister pack [Aust R 152177]

 

2.       The test method to be used is method QC.NUS.OPN.bza.tab.002.C/2.

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.